After the termination of a major global collaboration with Boehringer Ingelheim GmbH in 2020, Bridge Biotherapeutics, Inc.'s hopes for its U-turned autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF) are rising as it gears up for a global Phase II trial.
Bridge Biotherapeutics Rebounds After IPF Deal Roller Coaster Ride
Multiple R&D Events This Year
Bridge Biotherapeutics' CEO talks to Scrip about plans for autotaxin inhibitor returned by Boehringer Ingelheim in 2020, as well as other major R&D developments and priorities for this year and beyond.
More from South Korea
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.
• By
A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.
• By
Cross-Asian initiative has already brought several South Korean gene and cell therapy startups and Japanese VCs closer, with further hopes for product development and launches in Japan, regulatory harmonization and gliobalization.
• By
The latest activity in the South Korean biotech sector includes IPOs by Orum and Dongkook Life, as well as progress with ADCs at multiple firms.